Journals / Meandros Medical And Dental Journal / 2015 / Cilt: 16 - Sayı: 2

Uzun Süreli ve Tekrarlı Rapamisin ve Melatonin Uygulaması Sonrası Metastatik Meme Kanseri Hücre Hattında DNA Metiltransferaz Ekspresyon ve Proliferasyon Durumu

DNA Methyltransferase Expression and Proliferation Status of Metastatic Breast Cancer Cell Line After Prolonged and Repeated Rapamycin and Melatonin Application

Pages
50–58
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Real-time RT-PCR analysis of DNMT-1 gene expression showed a decreased expression level in the Melatonin given group compared to the control group and an increased expression level was seen in the Rapamycin and Rapamycin + Melatonin administrated groups compared to the control group.Conclusion: As a result, it was found that Rapamycin is more effective in metastatic breast cancer cells than Melatonin, both in the manner of cell viability and expressional changes of Ki67, DNMT-1, DNMT-3a and p53

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to investigate the effects of Rapamycin and Melatonin and their combination on deoxyribonucleic acid (DNA) methylation and cell proliferation in a estrogen receptor (ER)-negative breast cancer cell line (4T1 cell line).Materials and Methods: Four groups were designed with 4T1 cell line depending on drug combination (control, Rapamycin, Melatonin, Rapamycin + Melatonin) and their administration on different time periods (24, 48 and 72 hours).
📊
Key Findings & Data:The drugs were administrated for 1, 2 and 3 times, respectively for these time periods.
💡
Conclusion & Impact:Real-time RT-PCR analysis of DNMT-1 gene expression showed a decreased expression level in the Melatonin given group compared to the control group and an increased expression level was seen in the Rapamycin and Rapamycin + Melatonin administrated groups compared to the control group.Conclusion: As a result, it was found that Rapamycin is more effective in metastatic breast cancer cells than Melatonin, both in the manner of cell viability and expressional changes of Ki67, DNMT-1, DNMT-3a and p53
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to investigate the effects of Rapamycin and Melatonin and their combination on deoxyribonucleic acid (DNA) methylation and cell proliferation in a estrogen receptor (ER)-negative breast cancer cell line (4T1 cell line).Materials and Methods: Four groups were designed with 4T1 cell line depending on drug combination (control, Rapamycin, Melatonin, Rapamycin + Melatonin) and their administration on different time periods (24, 48 and 72 hours). The drugs were administrated for 1, 2 and 3 times, respectively for these time periods. All samples were counted; immunostained (Ki67, DNA methyltransferase-1 (DNMT-1), DNA methyltransferase-3a (DNMT-3a) and p53) and real-time polymerase chain reaction (PCR) (DNMT-1 and DNMT-3a) was performed.Results: The live/dead cell ratios were decreased in the Rapamycin and Rapamycin + Melatonin applied groups. Ki67 immunostaining showed that there was a decreased proliferation in the drug applied groups at 48th hours compared to the 24th hours. Also DNMT-1 expressions were decreased at 72th hour compared to that at 24thhour in all groups, especially in the Rapamycin administrated group. Adversely, DNMT-3a expression was increased at 72th hour compared to that at 24th hour in the groups, especially in the Rapamycin administrated group. Furthermore, an increased expression of p53 was seen in the drug given groups (highest in the Rapamycin applied group) when the time prolonged. Real-time RT-PCR analysis of DNMT-1 gene expression showed a decreased expression level in the Melatonin given group compared to the control group and an increased expression level was seen in the Rapamycin and Rapamycin + Melatonin administrated groups compared to the control group.Conclusion: As a result, it was found that Rapamycin is more effective in metastatic breast cancer cells than Melatonin, both in the manner of cell viability and expressional changes of Ki67, DNMT-1, DNMT-3a and p53

Özet

Amaç: Bu çalışmanın amacı; Rapamisin, Melatoninin ve bunların birlikte kullanımlarının, östrojen reseptörü (ER)-negatif meme kanseri hücre hattının (4T1 hücre hattı) deoksiribonükleikasit (DNA) metilasyonu ve hücre proliferasyonu üzerine olan etkilerini incelemekti.Gereç ve Yöntemler: İlaç kombinasyonlarına (kontrol, Rapamisin, Melatonin, Rapamisin + Melatonin) ve bu ilaçların farklı zaman dilimlerinde (24, 48 ve 72 saat) uygulanmalarına bağlı olarak; 4T1 hücre hattı ile dört farklı grup oluşturuldu. İlaçlar, bu zaman dilimleri için sırasıyla; 1, 2 ve 3 defa uygulanmıştır. Tüm örnekler ile hücre sayımı, immun-boyama (Ki67, DNA metiltranferaz-1 (DNMT-1), DNA metiltransferaz-3a (DNMT-3a) ve p53 antikorları ile) ve Real-time PCR (polimeraz zincir reaksiyonu) (DNMT-1 ve DNMT-3a primerleri ile) yapıldı.Bulgular: Rapamisin ve Rapamisin + Melatonin uygulanmış olan gruplarda canlı/ölü hücre oranı düşüş göstermiştir. İlaç uygulanan gruplarda 24. saate kıyasla 48. saatte, Ki67 immun-boyaması ile proliferasyonda düşüş gözlenmiştir. Ayrıca DNMT-1 ekspresyonları; 72. saatte, 24. saate kıyasla tüm gruplarda, özellikle rapamisin uygulanan grupta, düşüş göstermiştir. DNMT-3a ekspresyonu ise 72. saatte, 24. saate kıyasla tüm gruplarda, özellikle rapamisin uygulanan grupta, artış göstermiştir. İlaç verilen gruplarda (en çok rapamisin uygulanmış olan grupta), ilaç uygulaması arttıkça ve süre geçtikçe artan p53 ekspresyonu gözlendi. DNMT-1 gen ekspresyonunun Real-time RT-PCR sonuçlarına göre, DNMT-1 gen ekspresyonu Melatonin uygulanan grupta kontrol grubuna kıyasla düşme eğilimi gösterirken, rapamisin ve Rapamisin + Melatonin uygulanan gruplarda kontrol grubuna göre artmıştır. DNMT-3a gen ekspresyonunun Real-time RT-PCR sonuçlarına göre ise, DNMT-3a gen ekspresyonu, tüm ilaç uygulanan gruplarda kontrol grubuna kıyasla artmıştır. Sonuç: Rapamisinin, metastatik meme kanseri hücrelerinde hem hücre canlılığı açısından hem de Ki67, DNMT-1, DNMT-3a ve p53'ün ekspresyonel değişimleri açısından Melatoninden daha etkili olduğu bulunmuştur.

🔖

Cite This Article

GÖKMEN, E., ERGİN, K. (2015). Uzun Süreli ve Tekrarlı Rapamisin ve Melatonin Uygulaması Sonrası Metastatik Meme Kanseri Hücre Hattında DNA Metiltransferaz Ekspresyon ve Proliferasyon Durumu. Meandros Medical And Dental Journal, Cilt: 16 - Sayı: 2, 50–58. https://ajindex.com/articles/282849

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Widodo I, Dwianingsih EK, Triningsih E, Utoro T, Soeripto. Clinicopathological features of indonesian breast cancers with different molecular subtypes. Asian Pac J Cancer Prev 2014; 15: 6109-13.
  2. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652-7.
  3. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. Journal Clin Pathol 2004; 57: 675-81. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17: 330-9.
  4. Denis H, Ndlovu MN, Fuks F. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep 2010; 12: 647-56. Seto B. Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer. Clin Transl Med 2012; 1: 29. Baldwin WS, Travlos GS, Risinger JI, Barrett JC. Melatonin does not inhibit estradiol-stimulated proliferation in MCF-7 and BG-1 cells. Carcinogenesis 1998; 19: 1895-900.
  5. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso- González C, et al. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 2006; 30: 118-28.
  6. Cos S, Fernández R, Güézmes A, Sánchez-Barceló EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 1998; 58: 4383-90.
  7. Cos S, Blask DE, Lemus-Wilson A, Hill AB. Effects of melatonin on the cell cycle kinetics and estrogen-rescue of MCF-7 human breast cancer cells in culture. J Pineal Res 1991; 10: 36-42.
  8. Jardim-Perassi BV, Arbab AS, Ferreira LC, Borin TF, Varma NR, Iskander AS, et al. Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. PLoS One 2014; 9: 85311. Lv D, Zhang Y, Kim HJ, Zhang L, Ma X. CCL5 as a potential immunotherapeutic target in triple-negative breast cancer. Cel Mol Immunol 2013; 10: 303-10.
  9. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. omparison of triple-negative and estrogen receptor-positive/ progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease char